We are live on ! Find out more
BGA

Belmont Global Advisors Portfolio holdings

AUM $106M
1-Year Est. Return 2.89%
This Fund
S&P 500
This Quarter Est. Return
+8.71%
1 Year Est. Return
-2.89%
3 Year Est. Return
+81.05%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$1.54M
Cap. Flow
-$4.07M
Cap. Flow %
-3.85%
Top 10 Hldgs %
66.08%
Holding
96
New
32
Increased
14
Reduced
12
Closed
27

Top Buys

Rank Stock Value
1
TCRT icon
Alaunos Therapeutics
TCRT
+$2.18M
2
IMPV
Imperva, Inc.
IMPV
+$1.32M
3
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$1.08M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.06M
5
BBW icon
Build-A-Bear
BBW
+$979K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.29M
2
HD icon
Home Depot
HD
+$1.28M
3
PANW icon
Palo Alto Networks
PANW
+$1.04M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$960K
5
CHKP icon
Check Point Software Technologies
CHKP
+$797K

Sector Composition

Rank Sector Weight
1 Healthcare 26.08%
2 Technology 5.99%
3 Consumer Discretionary 3.69%
4 Industrials 2.56%
5 Consumer Staples 2.39%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

LOT
Lombard Odier Transatlantic Montreal, Quebec, Canada $105M AUM 10.28% 1-Year Est. Return
EC
Eachwin Capital New York $108M AUM 14.45% 1-Year Est. Return
SAMNY
Samsung Asset Management (New York) New York $109M AUM 14.34% 1-Year Est. Return
DCMM
DG Capital Management (Massachusetts) Boston, Massachusetts $102M AUM 29.14% 1-Year Est. Return
PCM
Panning Capital Management New York $97.5M AUM 302.5% 1-Year Est. Return
SVGI
Sapphire Ventures (GPE) I Palo Alto, California $115M AUM 11.63% 1-Year Est. Return
EDRM
Edmond de Rothschild (Monaco) Monaco $116M AUM
EDRAML
Edmond de Rothschild Asset Management (Luxembourg) Luxembourg $95.2M AUM 19.45% 1-Year Est. Return

Belmont Global Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Belmont Global Advisors held 96 positions worth $106M, up 1.5% from $104M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Belmont Global Advisors withdrew a net $4.07M in Q3 2016, closing 27 positions and reducing 12 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $1.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 23% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Belmont Global Advisors opened a new position in Imperva, Inc. worth $1.53M.

  • Belmont Global Advisors's largest Q3 2016 buy was Imperva, Inc.: 28,500 shares worth $1.53M.
  • Belmont Global Advisors added most to Alaunos Therapeutics in Q3 2016, an estimated $2.18M increase.
  • Belmont Global Advisors's biggest Q3 2016 reduction was Fate Therapeutics, cutting an estimated $607K.
  • Belmont Global Advisors fully exited Acadia Pharmaceuticals in Q3 2016, selling an estimated $1.29M.
  • Belmont Global Advisors's ten largest holdings make up 66% of its $106M portfolio in Q3 2016.
  • Belmont Global Advisors opened 32 new positions and closed 27 in Q3 2016.
  • Belmont Global Advisors's portfolio value rose 1.5% quarter-over-quarter to $106M.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.